Authors: Noonan, M Karpel, JP Bensch, GW Ramsdell, JW Webb, DR Nolop, KB Lutsky, BN

Citation: M. Noonan et al., Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler, ANN ALLER A, 86(1), 2001, pp. 36-43

Authors: Fish, JE Karpel, JP Craig, TJ Bensch, GW Noonan, M Webb, DR Silverman, B Schenkel, EJ Rooklin, AR Ramsdell, JW Nathan, R Leflein, JG Grossman, J Graft, DF Gower, RG Garay, SM Frigas, E DeGraff, AC Bronsky, EA Bernstein, DI Berger, W Shneyer, L Nolop, KB Harrison, JE

Citation: Je. Fish et al., Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related duality of life in patients with severe persistent asthma, J ALLERG CL, 106(5), 2000, pp. 852-860

Authors: Ramsdell, JW Grossman, JA Stephens, JM Botteman, MF Arocho, R

Citation: Jw. Ramsdell et al., A short-term cost-of-treatment model for type 2 diabetes: Comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose, AM J M CARE, 5(8), 1999, pp. 1007-1024

Authors: Ramsdell, JW Klinger, NM Ekholm, BP Colice, GL

Citation: Jw. Ramsdell et al., Safety of long-term treatment with HFA albuterol, CHEST, 115(4), 1999, pp. 945-951

Authors: Ramsdell, JW Colice, GL Ekholm, BP Klinger, NM

Citation: Jw. Ramsdell et al., Cumulative dose response study comparing HFA-134a albuterol sulfate and conventional CFC albuterol in patients with asthma, ANN ALLER A, 81(6), 1998, pp. 593-599